Last edition
News about
Novartis Builds Global Biomedical Research Centre in San Diego
Novartis launches construction of a 466,000-square-foot biomedical research centre in San Diego, set to open in 2029, strengthening global drug discovery and advancing neuroscience, oncology and next-generation therapies.
FDA Accepts IND for Affinia's AFTX-201 Gene Therapy in BAG3 Dilated Cardiomyopathy
Affinia Therapeutics receives FDA clearance to begin clinical testing of AFTX-201, a next-generation AAV gene therapy for BAG3-associated dilated cardiomyopathy, with Phase 1/2 UPBEAT trial set to begin in 2026.
Roche reported positive late-breaking Phase III ACTRIMS data showing fenebrutinib reduced disability progression in Primary Progressive Multiple Sclerosis (PPMS), demonstrating non-inferiority to OCREVUS and reinforcing its potential as a first-in-class oral BTK inhibitor.
FDA Grants Orphan Drug Designation to Zenocutuzumab for Rare Cholangiocarcinoma Subset
Partner Therapeutics secures Orphan Drug Designation for zenocutuzumab-zbco in NRG1 fusion-positive cholangiocarcinoma, strengthening development of targeted therapy for this aggressive rare cancer.
Innovent Collaborates with Lilly to Develop New Medicines in Oncology and Immunology
The agreement grants Lilly an exclusive licence to develop and commercialise the programmes worldwide outside Greater China, while Innovent retains rights in Greater China.
Health Canada Authorises Livmarli Tablet for Cholestatic Pruritus in Alagille Syndrome
Mirum Pharmaceuticals receives Health Canada approval for Livmarli tablet formulation, expanding dosing options for eligible Alagille syndrome patients with cholestatic pruritus.
Breckenridge Pharmaceutical enters a strategic collaboration with Medichem Solutions to supply injectable medicines for anaesthesia, critical care and emergency use, strengthening its presence in the US hospital segment.
Hologic's Aptima HPV Assay Receives US FDA Approval for Primary Cervical Cancer Screening
US FDA approves Hologic’s mRNA-based Aptima HPV assay for clinician-collected primary screening, expanding cervical cancer testing options and enhancing early detection of high-risk infections.
UK MHRA Updates Safety Information on Semaglutide Over Rare NAION Vision Risk
UK MHRA flags a very rare risk of NAION linked to semaglutide, urging patients to seek immediate medical attention for sudden changes in vision.
Lishan Biotech secures exclusive worldwide rights to develop and commercialise BMC128, a Phase I microbiome-based immunotherapy candidate showing early promise in lung and renal cancers.
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy